In conclusion, the safety profiles and the preliminary efficacy of durvalumab in combination with tremelimumab revealed through this study support further clinical development of anti‐PD‐1/PD‐L1 and anti‐CTLA‐4 combinations in additional tumor types. This evidence concerns the gene CD274 and neoplasm.